[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550127":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":33,"collaborators":7,"id":35,"slug":7,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":53,"overallStatus":60,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Romain Brousse, MD, PhD","CONTACT","+33156017043","Romain.brousse@aphp.fr",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Boffa Jean-Jacques, MD, PhD","+33156016029","Jean-jacques.boffa@aphp.fr",[19],{"facility":20,"status":7,"city":21,"state":7,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Néphrologie & Dialyses department, Tenon Hospital","Paris","75020","France",{"type":25,"coordinates":26},"Point",[27,28],2.3488,48.85341,{"lat":28,"lon":27},[31,32],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100550127",false,"NCT06443034","Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1","Predictive Determinants of Nephrotic Syndrome Remission in Patients With Focal Segmental Glomerulosclerosis or Minimal Change Disease and At-risk Polymorphism of APOL1 Gene","NEPHROL1","Inclusion Criteria:\n\n* Adult patients followed in 6 nephrology centers between 01\u002F01\u002F2016 and 01\u002F06\u002F2024.\n* With characterization of APOL1 gene risk status\n* Proteinuria\u002Fcreatinuria ratio \\> 3 g\u002Fg at diagnosis of renal disease (within 48 hours of the diagnostic renal biopsy)\n* Hypoalbuminemia \\\u003C 30 g\u002FL at diagnosis of renal disease (within 48 h of diagnostic renal biopsy)\n* Minimal change disease or segmental and focal hyalinosis lesions on renal biopsy.\n\nExclusion Criteria:\n\n* Presence of diffuse deposits of immunoglobulins or complement fractions on immunofluorescence study\n* Presence of endo- or extracapillary hypercellular lesions on light microscopy\n* Opposition to the use of medical data","ALL","18 Years",{"count":45,"type":46},124,"ESTIMATED","OBSERVATIONAL","This is a multicentric retrospective observational cohort study.\n\nAs primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal change disease or focal segmental glomerulosclerosis, and an at-risk variant of the APOL1 gene.\n\nAs secondary objectives, this study aims:\n\n* To evaluate the benefit of corticosteroids in obtaining the remission of nephrotic syndrome\n* To identify the predictors of complete renal remission of nephrotic syndrome\n* To evaluate the benefit of corticosteroids in reducing the incidence of end-stage renal disease\n* To assess the adverse events of corticosteroids in patients treated with corticosteroids.",[50,51,52],"Nephrotic Syndrome","Focal Segmental Glomerulosclerosis","APOL1 Associated Kidney Disease",[54,55,56,57,58,59],"Nephrotic syndrome","Covid-19 associated nephropathy","human immunodeficiency virus associated nephropathy","APOL1 associated kidney disease","Focal segmental glomerulosclerosis","Minimal change disease","NOT_YET_RECRUITING","2024-06-03",{"date":63,"type":64},"2024-06-05","ACTUAL",{"date":66,"type":46},"2024-06-30",{"date":68,"type":46},"2024-12-30",{"name":5,"class":6},1]